X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2009) 2009
humans (1855) 1855
male (1494) 1494
female (1233) 1233
2-pyridinylmethylsulfinylbenzimidazoles (1190) 1190
lansoprazole (1107) 1107
omeprazole - analogs & derivatives (1071) 1071
adult (1025) 1025
middle aged (989) 989
proton pump inhibitors (890) 890
gastroenterology & hepatology (747) 747
omeprazole (713) 713
pharmacology & pharmacy (673) 673
aged (630) 630
anti-ulcer agents - administration & dosage (625) 625
omeprazole - administration & dosage (588) 588
helicobacter infections - drug therapy (545) 545
treatment outcome (535) 535
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (497) 497
anti-ulcer agents - therapeutic use (482) 482
rabeprazole (475) 475
drug therapy, combination (439) 439
helicobacter pylori (436) 436
omeprazole - therapeutic use (409) 409
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (337) 337
gastroesophageal reflux - drug therapy (327) 327
benzimidazoles - administration & dosage (314) 314
amoxicillin - administration & dosage (308) 308
pantoprazole (306) 306
drug administration schedule (299) 299
double-blind method (295) 295
proton pump inhibitor (290) 290
clarithromycin - administration & dosage (285) 285
anti-bacterial agents - administration & dosage (266) 266
animals (257) 257
dose-response relationship, drug (257) 257
prospective studies (257) 257
proton pump inhibitors - administration & dosage (252) 252
administration, oral (249) 249
omeprazole - pharmacology (241) 241
adolescent (240) 240
pharmacokinetics (234) 234
anti-ulcer agents - pharmacology (231) 231
abridged index medicus (224) 224
helicobacter pylori - drug effects (221) 221
time factors (221) 221
cross-over studies (217) 217
benzimidazoles - therapeutic use (210) 210
infection (199) 199
anti-ulcer agents - adverse effects (192) 192
2-pyridinylmethylsulfinylbenzimidazoles - adverse effects (187) 187
sulfoxides - administration & dosage (187) 187
rats (185) 185
aged, 80 and over (184) 184
hydrogen-ion concentration (184) 184
gastric acid - secretion (181) 181
enzyme inhibitors - administration & dosage (176) 176
cytochrome p-450 cyp2c19 (174) 174
anti-bacterial agents - therapeutic use (170) 170
proton pump inhibitors - therapeutic use (170) 170
medicine & public health (166) 166
omeprazole - adverse effects (164) 164
therapy (163) 163
benzimidazoles - pharmacology (162) 162
eradication (158) 158
amoxicillin (155) 155
2-pyridinylmethylsulfinylbenzimidazoles - pharmacology (152) 152
clarithromycin (152) 152
management (152) 152
omeprazole - pharmacokinetics (152) 152
amoxicillin - therapeutic use (148) 148
gastroesophageal reflux (148) 148
clarithromycin - therapeutic use (146) 146
ranitidine (145) 145
drug interactions (143) 143
young adult (142) 142
2-pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics (136) 136
peptic ulcer - drug therapy (136) 136
gastroesophageal-reflux disease (135) 135
anti-ulcer agents - pharmacokinetics (133) 133
triple therapy (132) 132
metronidazole - administration & dosage (131) 131
duodenal ulcer - drug therapy (130) 130
genotype (130) 130
sulfoxides - therapeutic use (130) 130
aryl hydrocarbon hydroxylases - genetics (129) 129
efficacy (129) 129
follow-up studies (127) 127
enzyme inhibitors - therapeutic use (126) 126
gastroenterology (126) 126
gastric acidity determination (123) 123
area under curve (121) 121
double-blind (121) 121
duodenal-ulcer (118) 118
intragastric ph (118) 118
proton pump inhibitors - adverse effects (116) 116
gastroesophageal reflux disease (114) 114
stomach ulcer - drug therapy (114) 114
helicobacter infections - complications (113) 113
esophagitis (111) 111
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1884) 1884
Japanese (76) 76
German (34) 34
Russian (33) 33
Spanish (18) 18
Chinese (15) 15
French (8) 8
Korean (5) 5
Czech (2) 2
Hungarian (2) 2
Norwegian (2) 2
Croatian (1) 1
Danish (1) 1
Italian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9862, pp. 205 - 213
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9790, pp. 507 - 514
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2008, Volume 47, Issue 1, pp. 47 - 59
Objectives: To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual... 
Dabigatran etexilate | Thrombin inhibitors | Elderly | Research and development | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Dabigatran etexilate, pharmacokinetics | Thrombin inhibitors, pharmacokinetics | REPLACEMENT | APTT | MANAGEMENT | THERAPY | VENOUS THROMBOEMBOLISM | TOTAL HIP | DISEASE | ETEXILATE | PHARMACOLOGY & PHARMACY | Anticoagulants - administration & dosage | Area Under Curve | Humans | Thrombin - antagonists & inhibitors | Pyridines - pharmacokinetics | Biological Availability | Male | Dabigatran | Flatulence - chemically induced | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Diarrhea - chemically induced | Tandem Mass Spectrometry | Hematoma - chemically induced | Capsules | Benzimidazoles - administration & dosage | Aged, 80 and over | Chromatography, Liquid | Anti-Ulcer Agents - pharmacology | Female | Benzimidazoles - blood | Pyridines - administration & dosage | Administration, Oral | Benzimidazoles - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Anticoagulants - blood | Pyridines - blood | Blood Coagulation - drug effects | Partial Thromboplastin Time | Sex Factors | Aged | Anticoagulants - pharmacokinetics | Metabolic Clearance Rate - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Index Medicus
Journal Article
Helicobacter, ISSN 1083-4389, 04/2013, Volume 18, Issue 2, pp. 129 - 134
Background The eradication of Helicobacter pylori has been always a concern. In the present study, we aimed to compare two novel treatments in Iran. Method... 
hybrid | clarithromycin | sequential | ran | elicobacter pylor | Hybrid | Clarithromycin | Helicobacter pylori | Iran | Sequential | METAANALYSIS | EFFICACY | PROTON-PUMP INHIBITOR | ANTIBIOTIC-RESISTANCE | MICROBIOLOGY | AMOXICILLIN | REGIMENS | TRIPLE THERAPY | INFECTION | 1ST-LINE | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Humans | Middle Aged | Tinidazole - adverse effects | Helicobacter pylori - drug effects | Male | Tinidazole - therapeutic use | Anti-Bacterial Agents - therapeutic use | Peptic Ulcer - microbiology | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Anti-Ulcer Agents - adverse effects | Treatment Outcome | Clarithromycin - therapeutic use | Anti-Ulcer Agents - administration & dosage | Tinidazole - administration & dosage | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Helicobacter Infections - microbiology | Urea | Care and treatment | Amoxicillin | Clinical trials | Helicobacter infections | Comparative analysis | Antiulcer drugs | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 1, pp. 134 - 141
Journal Article
Helicobacter, ISSN 1083-4389, 06/2013, Volume 18, Issue 3, pp. 180 - 186
Background The eradication rate with PPI-based standard triple therapy for Helicobacter pylori infection has fallen considerably. One recent innovation is... 
quadruple | concomitant | Helicobacter pylori | eradication | sequential | Quadruple | Sequential | Eradication | Concomitant | METAANALYSIS | MANAGEMENT | CONSENSUS CONFERENCE | CLARITHROMYCIN RESISTANCE | REGIMEN | MICROBIOLOGY | KOREA | TRIAL | QUADRUPLE THERAPY | TRIPLE THERAPY | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Proton Pump Inhibitors - pharmacology | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Rabeprazole | Anti-Bacterial Agents - therapeutic use | Proton Pump Inhibitors - administration & dosage | Metronidazole - therapeutic use | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Anti-Ulcer Agents - pharmacology | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Breath Tests | Treatment Outcome | Proton Pump Inhibitors - therapeutic use | Pilot Projects | Urea - therapeutic use | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | Aged | Anti-Bacterial Agents - pharmacology | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Urea | Care and treatment | Patient outcomes | Amoxicillin | Helicobacter infections | Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 01/2012, Volume 35, Issue 1, pp. 56 - 65
Background The eradication rates following standard triple therapy for Helicobacter pylori infection are declining worldwide. Recent studies have shown that... 
METAANALYSIS | MANAGEMENT | EFFICACY | ERADICATION RATES | PROTON-PUMP INHIBITOR | KOREAN PATIENTS | PHARMACOLOGY & PHARMACY | QUADRUPLE | GASTROENTEROLOGY & HEPATOLOGY | ANTIMICROBIAL RESISTANCE | FAILURE | CONSENSUS REPORT | Humans | Middle Aged | Male | Rabeprazole | Peptic Ulcer - microbiology | Time Factors | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Republic of Korea | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Endoscopy, Gastrointestinal | Treatment Outcome | Anti-Ulcer Agents - administration & dosage | Amoxicillin - adverse effects | Aged | Helicobacter pylori - isolation & purification | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Helicobacter Infections - microbiology | Medical colleges | Medical research | Clinical trials | Standards | Helicobacter pylori | Amoxicillin | Medicine, Experimental | Medical care | Helicobacter infections | Comparative analysis | Health aspects | Quality management | Infection | Clarithromycin | Hospitals | Metronidazole | Index Medicus
Journal Article
Stroke, ISSN 0039-2499, 03/2015, Volume 46, Issue 3, pp. 722 - 731
BACKGROUND AND PURPOSE—There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the... 
LANSOPRAZOLE | drug interactions | PROPENSITY SCORE | CARDIOVASCULAR EVENTS | CORONARY | OMEPRAZOLE | stroke | CLINICAL NEUROLOGY | pharmacoepidemiology | proton pump inhibitors | CONCOMITANT USE | platelet aggregation inhibitors | cohort studies | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | OUTCOMES | Medicaid | JAPANESE PATIENTS | ARTERY-DISEASE | Rabeprazole - adverse effects | Esomeprazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Male | Risk | Drug Therapy, Combination - adverse effects | Stroke - chemically induced | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Stroke - epidemiology | Retrospective Studies | Brain Ischemia - chemically induced | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Data Interpretation, Statistical | Stroke - prevention & control | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Proportional Hazards Models | Omeprazole - adverse effects | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Lansoprazole - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Rabeprazole - administration & dosage | Index Medicus | Pharmacoepidemiology | Stroke | Drug interactions | Cohort studies | Platelet aggregation inhibitors | Proton pump inhibitors
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 01/2010, Volume 152, Issue 1, pp. 1 - 9
Journal Article
Journal Article